Octagon Capital Advisors as of Dec. 31, 2024
Portfolio Holdings for Octagon Capital Advisors
Octagon Capital Advisors holds 31 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Apellis Pharmaceuticals (APLS) | 15.8 | $96M | 3.0M | 31.91 | |
| Arrivent Biopharma (AVBP) | 9.0 | $55M | 2.1M | 26.64 | |
| Dianthus Therapeutics (DNTH) | 7.6 | $46M | 2.1M | 21.80 | |
| Insmed Com Par Call Option (INSM) | 6.6 | $40M | 582k | 69.04 | |
| Centessa Pharmaceuticals Sponsored Ads Put Option (CNTA) | 5.9 | $36M | 2.1M | 16.75 | |
| Verona Pharma Sponsored Ads (VRNA) | 4.4 | $27M | 571k | 46.44 | |
| Nuvation Bio Com Cl A (NUVB) | 4.0 | $25M | 9.2M | 2.66 | |
| Cogent Biosciences (COGT) | 3.5 | $22M | 2.8M | 7.80 | |
| Scholar Rock Hldg Corp (SRRK) | 3.5 | $21M | 488k | 43.22 | |
| Mind Medicine Mindmed Com New (MNMD) | 3.5 | $21M | 3.0M | 6.96 | |
| Ocular Therapeutix (OCUL) | 3.4 | $21M | 2.4M | 8.54 | |
| Taysha Gene Therapies Com Shs (TSHA) | 3.0 | $18M | 11M | 1.73 | |
| Miragen Therapeutics (VRDN) | 2.7 | $17M | 870k | 19.17 | |
| Gossamer Bio (GOSS) | 2.7 | $17M | 18M | 0.90 | |
| Dyne Therapeutics (DYN) | 2.6 | $16M | 668k | 23.56 | |
| Pharvaris N V (PHVS) | 2.5 | $15M | 778k | 19.17 | |
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 2.2 | $13M | 1.1M | 11.80 | |
| Merus N V (MRUS) | 2.1 | $13M | 308k | 42.05 | |
| Erasca (ERAS) | 2.1 | $13M | 5.1M | 2.51 | |
| Bridgebio Pharma (BBIO) | 2.0 | $12M | 442k | 27.44 | |
| Syndax Pharmaceuticals (SNDX) | 2.0 | $12M | 904k | 13.22 | |
| Kalvista Pharmaceuticals (KALV) | 1.9 | $12M | 1.4M | 8.47 | |
| Unicycive Therapeutics | 1.3 | $7.9M | 10M | 0.79 | |
| Regulus Therapeutics | 1.3 | $7.7M | 4.8M | 1.58 | |
| Perspective Therapeutics Com New (CATX) | 1.2 | $7.4M | 2.3M | 3.19 | |
| Neurogene (NGNE) | 1.1 | $6.9M | 303k | 22.86 | |
| Allovir | 0.8 | $4.7M | 11M | 0.42 | |
| Atyr Pharma Com New (ATYR) | 0.5 | $3.3M | 900k | 3.62 | |
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 0.4 | $2.6M | 250k | 10.50 | |
| Mersana Therapeutics | 0.2 | $1.4M | 992k | 1.43 | |
| Nuvation Bio *w Exp 02/10/202 (NUVB.WS) | 0.1 | $831k | 312k | 2.66 |
